Soy supplements may reduce bone resorption during menopause
MedWire News: Soy isoflavone supplements could increase bone mineral density in menopausal women by reducing bone resorption, thereby reducing fracture risk, report researchers.
Soy isoflavones contain phyto-estrogens with structures similar to estrogen, which can improve bone turnover, write Kyoko Taku (National Institute of Health and Nutrition, Tokyo, Japan) and colleagues.
Taku and team reviewed trials reporting the effect of soy isoflavones on the bone resorption marker urinary deoxypyridinoline (DPD, 10 trials, n = 887), and bone formation markers serum bone alkaline phosphatase (BAP, 10 trials, n = 1210), and serum osteocalcin (OC, 8 trials n = 830).
Daily ingestion of approximately 56 mg soy isoflavones for 10 weeks to 12 months significantly decreased DPD by 14.1 percent compared with baseline, and by 18 percent compared with placebo.
This decrease in bone resorption may mean a reduction in the long-term risk of fracture, say Taku et al.
Additionally, a non-significant 8 percent reduction in BAP and 10.3 percent reduction in OC was observed after an average daily supplementation of 84 mg and 73 mg of soy isoflavones for up to 12 months, respectively.
"Soy isoflavone supplements moderately decreased the bone resorption marker urinary DPD and showed no significant effects on the bone formation markers serum BAP and OC in menopausal women," Taku and co-authors conclude.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
By MedWire Reporters